CAR T cell therapy for central nervous system solid tumors: current progress and future directions

Area of Science:

• Pediatric Oncology
• Neuro-oncology
• Immunotherapy

Background:

• Central nervous system (CNS) tumors are the second most common pediatric cancer and the leading cause of cancer-related death in children.
• High-risk pediatric CNS tumors have poor prognoses with current standard treatments, necessitating novel therapeutic strategies.
• CAR T cell therapy is an emerging immunotherapy with early reported clinical responses in this patient population.

Purpose of the Study:

• To review the clinical efficacy and toxicity of CAR T cell therapy for pediatric CNS tumors.
• To analyze antigen heterogeneity and challenges in the clinical implementation of CAR T cell therapy.
• To provide a broader perspective on immunotherapies, including TILs, NK, and LAK cells, for pediatric CNS malignancies.

Main Methods:

• Comprehensive analysis of reported clinical trials and literature on CAR T cell therapy for pediatric CNS tumors.
• Evaluation of systemic versus locoregional delivery methods for CAR T cells.
• Inclusion of studies on other immunotherapeutic approaches like tumor-infiltrating lymphocytes (TILs), NK cells, and lymphokine-activated killer (LAK) cells.

Main Results:

• CAR T cell therapy has demonstrated early objective clinical responses in pediatric CNS tumors.
• Systemic and locoregional delivery methods present distinct toxicity profiles.
• Antigen heterogeneity poses a significant challenge for effective CAR T cell targeting in CNS tumors.

Conclusions:

• CAR T cell therapy represents a promising alternative for high-risk pediatric CNS tumors.
• Addressing challenges in delivery, antigen targeting, and clinical implementation is crucial for maximizing therapeutic potential.
• A broader view of immunotherapies offers a comprehensive strategy for pediatric CNS malignancies.